SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg1/7/2008 6:04:31 AM
   of 933
 
2008 Infinity Goals and Financial Guidance

* Launch a Phase 3 registration trial of IPI-504 in GIST: Pending ongoing consultation with advisors and regulatory authorities, and analysis of data from the ongoing fully-expanded Phase 1 clinical trial, Infinity, in collaboration with its partner MedImmune (a unit of AstraZeneca), expects to launch a registration trial of IPI-504 in refractory GIST in the third quarter of 2008.

* Initiate Phase 2 clinical trials of IPI-504 in additional indications: Infinity expects to continue broadening the commercial potential of IPI-504 by initiating Phase 2 trials in additional solid tumor indications;

* Commence a Phase 1 clinical study with an oral Hsp90 inhibitor: Infinity has been conducting comparative preclinical studies of its oral Hsp90 candidates, and, pending final analysis of preclinical data, expects to advance IPI-493 into the clinic in the first half of 2008;

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News